Notably, real‐world retrospective observational cohort studies (involving about 1.5 million patients with T2DM) using an emulated target trial design have also shown that compared to DPP‐4 inhibitors or other antihyperglycaemic agents, the use of GLP‐1RAs is associated with a significantly lower risk of liver‐related clinical events, such as incident cirrhosis, hepatic decompensation events, or hepatocellular carcinoma [37]. This evidence concerns the gene DPP4 and Cirrhosis.